Aarti Pharmalabs profit drops as finance costs and margins bite
The pharmaceutical firm reported a decline in annual profit to ₹176.20 crore, down from ₹238.03 crore in the previous year.
— 2 earlier stories on Aarti Pharmalabs Ltd. →What's new
- Standalone Q4 net profit fell to ₹62.03 crore from ₹88.85 crore a year ago.
- Full-year net profit dropped to ₹176.20 crore from ₹238.03 crore.
- The board recommended a final dividend of ₹2 per share.
Why this matters
The results show a clear trend of margin compression and rising finance costs weighing on the bottom line. This is a routine disclosure that confirms the pressure on profitability seen throughout the year.
What we're watching
- Whether the company can stabilize margins in the coming quarters.
- Any management commentary on the trajectory of finance costs.
- The impact of the proposed dividend on cash reserves.
The full read
Aarti Pharmalabs closed FY2026 with a sharp decline in profitability as rising finance costs and margin compression took hold. Standalone net profit for the full year landed at ₹176.20 crore, a significant drop from the ₹238.03 crore recorded in the previous year.
Margins are shrinking.
The trend persisted into the final quarter, where standalone net profit fell to ₹62.03 crore from ₹88.85 crore a year earlier, and the board has recommended a final dividend of ₹2 per share to appease shareholders despite the cooling performance. These results are backward-looking and largely align with market expectations for the mid-cap pharmaceutical player, yet the core challenge remains the company's ability to manage its cost structure in an environment where finance expenses are aggressively eating into margins.
Questions answered
- How did Aarti Pharmalabs' annual profit compare to the previous year?
- Full-year net profit fell to ₹176.20 crore, down from ₹238.03 crore in the prior year.
- What was the standalone profit for the final quarter?
- Standalone net profit for Q4 was ₹62.03 crore, compared to ₹88.85 crore in the same quarter last year.
- What dividend did the board recommend?
- The board recommended a final dividend of ₹2 per share.
- What factors contributed to the decline in profit?
- The company cited margin compression and higher finance costs as the primary drivers for the lower profitability.
Story so far
All notes on AARTIPHARM →- 26 May 2026 · 1:25 PM IST Aarti Pharmalabs profit drops as finance costs and margins bite
- today Aarti Pharmalabs profit slides as costs and forex losses mount
- today Aarti Pharmalabs profit drops as derivative accounting error surfaces